A controlled trial of idebenone in Huntington's disease

Neal G. Ranen, Carol E. Peyser, Joseph T. Coyle, Frederick W. Bylsma, Meeia Sherr, Leslie Day, Marshal F. Folstein, Jason Brandt, Christopher A. Ross, Susan E. Folstein

Research output: Contribution to journalArticlepeer-review

72 Scopus citations


One hundred patients with clinically diagnosed Huntington's disease (HD) were randomized to either idebenone, an antioxidant and enhancer of oxidative metabolism, or placebo, in a 1-year, double-blind, parallel-group study aimed at slowing the rate of progression of the disease. Ninety-one patients completed the study. There were no significant differences between groups on the primary outcome measures of the Huntington's Disease Activities of Daily Living Scale (ADL - an index of functional status) and the Quantified Neurologic Examination (QNE). Sample size calculations based on progression of the ADL and QNE in this study group revealed that a larger study group is necessary to detect any differences less than an almost complete halting of the disease. This argues for multicenter efforts for future therapeutic trials in HD.

Original languageEnglish (US)
Pages (from-to)549-554
Number of pages6
JournalMovement Disorders
Issue number5
StatePublished - 1996


  • Antioxidants
  • Huntington's disease
  • Idebenone

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'A controlled trial of idebenone in Huntington's disease'. Together they form a unique fingerprint.

Cite this